Overview

Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients

Status:
Not yet recruiting

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to use Chemo-radio-immunotherapy and maintenance therapy with Nivolumab and Ipilimumab in order to achieve improved outcome in patients with locally advanced cervical cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Universitätsklinikum Köln

Collaborator:

ZKS Köln

Treatments:

Immunologic Factors
Ipilimumab
Nivolumab